1043446-50-9

Upstream product

• 103-49-1 dibenzylamine 
• 912934-77-1 6-bromopyridine-2-sulfonyl chloride 
• 626-05-1 2,6-Dibromopyridine 

Downstream Products

• 1043446-52-1 C₂₇H₂₇N₃O₃S 
• 1043446-39-4 C⁽³⁷²⁾H₅₁₉₁ 
• 1259327-74-6 6-[3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pyridine-2-sulfonic acid amide 
• 1043446-58-7 6-[3-(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pyridine-2-sulfonic acid dibenzylamide 
• 1259327-72-4 6-[3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]pyridine-2-sulfonic acid dibenzylamide 
• 1043446-54-3 2-(6-dibenzylsulfamoylpyridin-2-ylamino)-2-methylpropionic acid methyl ester 
• 1043446-53-2 6-aminopyridine-2-sulfonic acid dibenzylamide 

Relevant academic research and scientific papers

SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: Formula (I) wherein R1 and G are defined herein.

Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer

A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of castration-resistant prostate cancer. Since CH4933468, which we reported previously, had a problem wit